Table 3 Univariate analysis of PFS.
PFS | |||
|---|---|---|---|
Parameters | Univariate analysis | ||
HR (95%CI) | Median PFS in years (95% CI) | p-value | |
Gender | |||
♂ | 1.3 (0.6–2.9) | 10 (3.6–16.3) | 0.432 |
♀ | 14 (2.8–25.2) | ||
Age | |||
≤ 60 y/o | 2.5 (1.1–5.8) | 14.0 (10.2–14.8) | 0.021 |
> 60 y/o vs | 10.0 (5.1–14.8) | ||
Histology | |||
FL | 1.3 (0.6–2.8) | Not reached | 0.427 |
MZL | 11.0 (5.2–16.8) | ||
Ann Arbor staging | |||
St. I | 0.9 (0.6–1.5) | 11.0 (7.4–14.6) | 0.751 |
St. II | Not reached | ||
Extranodal | |||
Yes | 1.2 (0.6–2.7) | 11.0 (4.5–17.5) | 0.541 |
No | Not reached | ||
RT as primary vs recurrent | |||
Primary treatment | 1.9 (0.7–5.1) | 14.0 (8.3–19.7) | 0.179 |
Recurrent treatment | 10.0 (3.8–10.0) | ||
Total dose of RT | |||
≤ 36.0 Gy | 1.4 (0.6–2.9) | 14.0 (8.7–19.7) | 0.425 |
> 36.0 Gy | 10.0 (4.9–15.1) | ||
Technique of RT | |||
3D/VMAT | 0.3 (0.1–0.8) | 14.0 (8.2–19.8) | 0.059 |
2D | 4.0 (1.1–6.9) | ||
Radiation field | |||
IFRT | 1.3 (0.6–2.7) | Not reached | 0.543 |
ISRT | 10 (4.3–15.7) | ||
